http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2407501-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28cecfc87bfdb41e74447f4815647949 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-88 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 |
| filingDate | 2003-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02620088fb6b6483b2ebbdc7510eb0ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19f10c3e68ff5bb2ef965648e37d2dcf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2621510bb0a358747cd40c091063bb2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55b7439d9e8e1002123be137449d3516 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc2302e7354774f30422a2c2cc4fec14 |
| publicationDate | 2005-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-2407501-A |
| titleOfInvention | Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell |
| abstract | Core-shell nanoparticles compris<WC 1>e: <SL> <LI>(a) a core which comprises a water insoluble polymer or copolymer, and <LI>(b) a shell which comprises a hydrophilic polymer or copolymer; </SL> ```said nanoparticles being obtainable by emulsion polymerization of a mixture comprising, in an aqueous solution, at least one water-insoluble monomer (especially a styrenic, <WC 1>acrylic or methacrylic monomer) to form the core and either: <SL> <LI>(i) a monomer of formula (I): <EMI ID=1.1 HE=15 WI=25 LX=406 LY=498 TI=CF> wherein R<1> represents hydrogen or methyl, and R<2> represents -COOAOH, -COO-A-NR<9>R<10> or -COO-A-N<+>R<9>R<10>R<11> X<->, in which A represents C1-20 <WC 1>alkylene, R<9>, R<10> and R<11> each independently represent hydrogen or C1-20<WC 1> alkyl and X represents halogen, sulphate, sulphonate or perchlorate, and a water-soluble polymer of formula (II) <EMI ID=1.2 HE=16 WI=40 LX=329 LY=914 TI=CF> wherein R<3> represents hydrogen or methyl, R<4> represents hydrogen or C1-20 alkyl, and n is an integer such that the polymer of formula (II) <WC 1>has a number-average molecular weight of at least 1000; or <LI>(ii) a hydrophilic copolymer which comprises repeating units of formulae </SL> (III) and (IV): <EMI ID=1.3 HE=29 WI=32 LX=403 LY=1554 TI=CF> <PC>wherein R<5> and R<7> each independently represent hydrogen or methyl, R<6> represents hydrogen, -A-NR<9>R<10> or -A-N<+>R<9>R<10>R<11> X<->, which A represents C1<WC 1>-20 alkylene, R<9>, R<10> and R<11> each independently represent hydrogen or C1-20 alkyl and X represents halogen, sulphate, sulphonate or perchlorate and R<8> represents C1-10 <WC 1>alkyl. The shell is formed by (i) or (ii). The nanoparticles may further comprise, adsorbed at the surface of the nanoparticles, at least one pharmacologically active agent, such as a disease-associated antigen The antigen may be a deoxyribonucleic acid, ribonucleic acid, oligodeoxynucleotide, oligonucleotide or protein; a microbial antigen or a cancer-associated antigen. A preferred antigen is a human immunodeficiency virus-l (HIV-1) antigen, especially an HIV -1 Tat protein or an immunogenic fragment thereof. Such materials may be used in a method of treatment of the human or animal body by therapy (especially for preventing or treating HN infection or AIDS) or in a diagnostic method practised on the human or animal body. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8905235-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009056344-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2044150-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2909094-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008065299-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2044150-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8268948-B2 |
| priorityDate | 2003-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 553.